|

Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease

RECRUITINGN/ASponsored by Oregon Health and Science University
Actively Recruiting
PhaseN/A
SponsorOregon Health and Science University
Started2024-03-05
Est. completion2025-12-31
Eligibility
Age40 Years – 90 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT06772220

Summary

This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.

Eligibility

Age: 40 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria.
2. Currently treated with levodopa at a minimum dose of 300 mg/day
3. Montreal Cognitive Assessment (MOCA) ≥15
4. Demonstrated capacity to provide informed consent.
5. 40-90 years of age
6. Estimated glomerular filtration rate ≥60
7. Absence of uncontrolled hypertension in medical history
8. Absence of insulin use

Exclusion Criteria:

\-

Conditions2

Parkinson's DiseaseParkinson's Disease

Locations1 site

Oregon Health & Science University (OHSU)
Portland, Oregon, 97239
Madeline Armendariz Sullivan503-501-8478PDResearch@ohsu.edu

Browse More Trials

Parkinson's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.